VERA - Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting | Benzinga
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN)
Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept's potential as long-term disease-modifying IgAN therapy
Atacicept showed continued protective titers to diphtheria and tetanus and balanced COVID infections vs. placebo in IgAN
BRISBANE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that three abstracts on the Company's product candidate atacicept in immunoglobulin A nephropathy (IgAN) have been selected for poster presentations at the American Society of Nephrology (ASN) Kidney Week 2023, which is taking place November 2–5, 2023, in Philadelphia, PA.
| Kidney Week Poster Presentation Details: |
| Poster Title: |
| ORIGIN 3: Pivotal Ph3 Study Evaluating Effect of Atacicept vs Placebo on Proteinuria and Renal Function Preservation in IgAN |
| Presenting Author: |
| Jonathan Barratt, Ph.D., FRCP, The Mayer Professor of Renal Medicine, University of Leicester, UK |
| Poster #: |
| INFO17-TH |
| Session Date, Time: |
| Thursday November 2, 2023 from 10:00 AM to 12:00 PM ET |
| Poster Title: |
| Atacicept 150mg Reduces Serum Gd-IgA1, a Biomarker Associated with Long-term Outcomes in IgAN: 36W Results from the Ph2b ORIGIN Study |
| Presenting Author: |
| Jonathan Barratt, Ph.D., FRCP, The ... |